FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approves a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC. The action updates the product's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

SUPPL AP for MOZOBIL (PLERIXAFOR)